[Form 4] LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock Insider Trading Activity

Rhea-AI Filing Summary

Insider filing shows grant vesting and holdings Stefan Galluppi, Chief Innovation Officer of LifeMD, Inc. (LFMD), reported an acquisition on 08/22/2025 of 30,000 shares of common stock resulting from a performance stock grant that vested on that date. The reported price is $0, indicating these were shares issued on vesting rather than purchased. After the transaction, Galluppi directly beneficially owns 110,449 shares and indirectly beneficially owns 1,644,800 shares through American Nutra Tech, LLC. The Form 4 was signed on 08/26/2025.

Positive

• Transparency: Filing clearly discloses vesting and total beneficial ownership
• No cash outflow: 30,000 shares issued on vesting at $0, not a market sale or purchase

Negative

• Concentration: Significant indirect ownership of 1,644,800 shares held by American Nutra Tech, LLC may concentrate voting power

Insights

Securities Analyst

TL;DR: An executive recognized vested performance shares, modest direct increase versus substantial indirect holdings via an affiliated entity.

The filing documents a non-cash acquisition of 30,000 common shares due to vesting of performance stock on 08/22/2025. The transaction does not involve cash consideration and therefore does not affect the companys cash position. The reporting person retains a significant indirect stake of 1,644,800 shares through American Nutra Tech, LLC, which may be material to ownership structure analysis. For investors, this is a routine insider vesting disclosure rather than a market transaction.

Corporate Governance Expert

TL;DR: Routine Form 4 reporting of vested equity; highlights link between executive and an affiliated LLC.

The disclosure clearly states the shares were granted as performance stock and vested on 08/22/2025, with no purchase price reported. The presence of a large indirect position via American Nutra Tech, LLC warrants review of any public disclosures about related-party ownership but is simply reported here as required. This Form 4 is a compliance filing documenting beneficial ownership changes rather than a corporate action.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Galluppi Stefan

(Last) (First) (Middle)

C/O LIFEMD, INC

236 FIFTH AVENUE, SUITE 400

(Street)

NEW YORK NY 10001

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LifeMD, Inc. [ LFMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Innovation Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/22/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/22/2025		A		30,000	A	$0(1)	110,449	D
Common Stock								1,644,800	I	By American Nutra Tech, LLC

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents grant of performance stock which vested on August 22, 2025

	/s/ Stefan Galluppi	08/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Stefan Galluppi report on Form 4 for LFMD?

He reported acquisition of 30,000 common shares on 08/22/2025 that vested from a performance stock grant.

Did Galluppi pay for the 30,000 shares reported on the Form 4?

No; the price is reported as $0, indicating the shares resulted from vesting rather than a purchase.

How many shares does Galluppi beneficially own after the transaction?

He beneficially owns 110,449 shares directly and 1,644,800 shares indirectly through American Nutra Tech, LLC.

What is Galluppis role at LifeMD as listed on the Form 4?

He is listed as Chief Innovation Officer and the form indicates an officer relationship.

When was the Form 4 signed?

The Form 4 bears the signature dated 08/26/2025.